Robert J. Gould, Interim President & CEO at Fulcrum Therapeutics, Inc. (FULC), sold 6,766 shares at $15.00 ($101K) on 2023-01-13, disclosed to the SEC on 2023-01-13.
Open-market sale of $101k FULC by Interim President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2022-06-08 | $1.2M | — | Filing → |